Viekirax Joins Fray in Hep C Market, Can It Crack into Harvoni’s Stronghold?

As AbbVie GK’s Viekirax (ombitasvir + paritaprevir + ritonavir) is to hit the Japanese hepatitis C space soon after its reimbursement listing on November 26, all eyes are now riveted on whether it can cut into archrival Harvoni’s (ledipasvir + sofosbuvir) strong grip on the market.

The hepatitis C market in Japan has been gathering steam since the debut of interferon (IFN)-free treatments last year. For genotype 1 hepatitis C, which accounts for 70-80% of hepatitis C patients in Japan, Bristol-Myers K.K.’s dual regimen, Daklinza (daclatasvir) and Sunvepra (asunaprevir), hit the shelves in September 2014 as the country’s first IFN-free oral therapy, followed by Harvoni of Gilead Sciences K.K. a year later.

News Calendar